- Case Report
- Open Access
Skull base metastases from a malignant solitary fibrous tumor of the liver. A case report and literature review
© Peng et al; licensee BioMed Central Ltd. 2011
Received: 20 October 2011
Accepted: 22 December 2011
Published: 22 December 2011
Solitary fibrous tumors (SFTs) of the liver are rarely described; only 38 cases have been reported in literature, most of which have shown benign clinical characteristics, and only 3 of these cases exhibited malignant variants. In this study, we present a 24-year-old woman with a 1-month history of a rapidly enlarging abdominal mass and a CT showing an exophytic heterogeneous liver mass with a firm parietal bone mass. The patient underwent a transcatheter arterial chemoembolization (TACE) before operation, and an extended right hepatectomy and craniectomy with a negative margin was performed under general anesthesia. The masses showed histological features of oval spindle cells haphazardly arranged in the classic short-storiform or so-called patternless pattern of solitary fibrous tumors. The tumor cells showed positive immunohistochemical reactions to CD34 and bcl-2. The tumor recurred in the residual liver 2 months after operation, metastatic osteoblastic lesions in the thoracic and lumbar vertebrae were identified 3 months after the operation, and lumbar vertebrae metastasis 7 months after operation paralyzed the patient. The patient underwent percutaneous ethanol injection therapy (PEI) and chemotherapy, but the patient died because of the uncontrolled tumor 16 months after the initial operation. To our knowledge, this is the first case of malignant solitary fibrous liver tumors with skeletal metastasis.
Solitary fibrous tumors (SFTs) are a rare soft-tissue neoplasm that was initially described most commonly in the pleural cavity. In the past decade, SFTs have been discovered at many body sites, including the liver (mostly the right lobe), orbits, superior respiratory tract, abdomen, breast and soft tissue [2–4]. SFTs are spindle cell neoplasms. The histogenesis of SFT has been a matter of contention and still has not been definitively discerned, but a mesenchymal origin is favored over a mesothelial origin.
More than 80% of SFTs are benign, asymptomatic and slow-growing tumors, but malignant and symptomatic forms, most often in the pleura, have been described [6, 7]. Clinical and radiological findings are not specific and cannot exclude malignancy. Preoperative cytology may be inconclusive or misleading. Notably, all SFTs that recurred or metastasized after resection in some larger series were ≥ 10 cm [8, 9]. In addition, several authors describe a histologically malignant component with increased cellularity and mitoses in otherwise benign-appearing SFTs, as a frequent occurrence in tumors that recurred or metastasized [8–10]. The recommended treatment of SFT is surgical resection. Despite this treatment, SFTs can recur and metastasize and have reported 10-year overall survival rates of 54-89% after a complete surgical resection .
However, surgical experience with SFTs of the liver is notably limited. In one series, 13.5% of 37 pleural SFTs metastasized . SFT is rarely located in the liver parenchyma and usually follows a benign course. Few case reports in the literature describe a local recurrence of liver SFT and even fewer describe metastases [12–16]. In this study, we report a case of malignant liver SFT with skeletal metastasis and discuss the clinical presentation, previous diagnoses, radiological characteristics, histopathological and immunohistiochemical features, surgical treatment, adjunctive therapy and prognosis of SFTs with a review of the literature.
The patient underwent four percutaneous ethanol-injection therapies (PEIs) and was treated with four rounds of chemotherapy that included adriamycin (40 mg on days 1-3), ifosfamide (3.0 g on days 1-4), and mesna (0.6 g IV 0 h, 4 h, and 8 h after IFO). Adjunctive radiation therapy was not administered. Despite the treatment, the tumor relapsed rapidly and was markedly enlarged. At follow-up seven months later, the patient was paralyzed; the patient died 16 months after the initial operation.
Clinicopathological features of the reported malignant cases of liver solitary fibrous tumors
Sezal Y, et al. 
32 × 30 × 12
spindle cells with oval-fusiform nuclei
Chan G, et al. 
27 × 24 × 12
CD34+, Bcl2+, CD99+
spindle-cell fibrosarcoma: highly cellular and pleomorphic, with areas of necrosis and a very high mitotic index (> 20/hpf)
> 9 months
Brochard C, et al. 
17 × 12 × 8
Tumor cells were polymorphic: small and round, spindle-shaped, voluminous with acidophilic cytoplasm, or with polymorphous nuclei.
Clinically, hepatic SFTs cause symptoms only after reaching a certain size, or when vital structures are involved. SFTs are not known to grow invasively, and the course of the disease following complete surgical resection is usually benign. The patient may be asymptomatic or have non-specific clinical manifestations, including increased abdominal volume and circumference and abdominal pain, distention, and discomfort, as seen in our patient, or other symptoms, such as anorexia, nausea, vomiting and weight loss. Fever, hypoglycemia, abnormal liver tests and biliary-duct compression that leads to cholestasis and progressive jaundice are less commonly seen [12, 13, 16, 19]. Laboratory results are usually normal; however, a few patients have had deranged liver function tests or elevated serum levels of a-fetoprotein [15, 19, 20]. Our patient had a high level of serum CA125.
The radiological findings of SFTs are unspecific and cannot distinguish between benign and malignant tumors. The diagnosis should be suspected if imaging reveals a solitary, highly vascular, well circumscribed, encapsulated mass that shows heterogeneous enhancement (due to the varied density of the collagen component) in CT and MRI images, especially if the enhancement is hypointense on the T2-weighted MRI and shows progressive enhancement in the delayed phase . Most benign or malignant liver tumors, including hemangiomas, hepatic adenomas, focal nodular hyperplasia, hepatocellular carcinomas, fibrolamellar hepatocellular carcinomas and peripheral mass-forming cholangiocarcinomas, are predominantly hyperintense on the T2-weighted images, and some have a delayed, persistent enhancement . The imaging features of benign and malignant solitary fibrous liver tumors appear to overlap. DWI can differentiate solitary fibrous tumors from malignant liver tumors. A whole-body fluorodeoxyglucose positron emission tomography (PET) showed that the mass had low metabolic activity and was probably benign [13, 22].
Several authors believe that fine-needle aspiration also helps to establish a diagnosis, if the tissue sample is adequate and the fine-needle aspiration can be analyzed for immunomarkers; there has been one successful case report of this practice . Other authors regard fine-needle biopsy to be inaccurate and do not recommend this practice. Large solid lesions of the liver (irrespective of the diagnosis), if deemed resectable at the pre- and intraoperative assessment, should be excised and sent for histological examination. Specimens obtained from a fine-needle biopsy only represent a small area of the tumor and may be misleading when entrapped proliferating bile ducts are mistaken for an adenocarcinoma, as in the present case. Alternatively, malignant foci may be missed, which would give a falsely reassuring result. Moreover, if the tumor is malignant, a percutaneous biopsy may seed tumor cells along the biopsy tract [7, 22].
The tumor may be found on either the right or left side of the liver. The average tumor weight, where available, was 3,184 g and ranged from 1,850 g to 4,500 g. The mean of the largest diameter was 17.8 cm (2-32 cm). Paula Novais  presented a case of a large solitary hepatic fibrous tumor that was unresectable at first. Two years later, another attempt at surgical resction was made, but a life-threatening surgical complication occurred during the postoperative course. Unresectable, rare, non-hepatocellular or bile duct tumors that arise within the hepatic parenchyma are a formal indication for liver transplantation; therefore, liver transplantation can be considered for non-resectable SFTs. Because the patient was stable for 4 years, the author questioned such aggressive treatments in asymptomatic patients, due to the natural history of this tumor, which is not well known, and the risk of other complications.
In the present case, the liver SFT diagnosis was based on the association of characteristic histological and immunohistochemical features (i.e., high cellular proliferation of spindle cells arranged in a storiform pattern) with the immunohistochemical staining profile of CD34 (+), Bcl-2 (+) and SM-actin (-). These characteristics differentiate SFTs from other liver tumors, such as primary hepatocellular carcinomas (CD34-negative), leiomyomas (smooth-muscle actin-positive and CD34-negative) and mesotheliomas (vimentin-positive, CD34-positive, cytokeratin-positive) . However, the CD34 antibody is not specific for SFT diagnosis and can be positive in angiosarcomas and gastrointestinal stromal tumors.
A hepatic SFT is often a benign neoplasm that has a good prognosis after surgery without recurrence. Most authors believe that postoperative adjuvant chemotherapy or radiotherapy should be reserved for incomplete resections and/or pathological features of malignancy [25, 26]. Currently, the combination of doxorubicin and ifosfamide is the standard systemic chemotherapy regimen for many subtypes of soft-tissue sarcomas. Gemcitabine with docetaxel has also emerged as a good therapeutic choice for these patients. Although cases of SFT that respond to these chemotherapeutic agents have been reported sporadically, no systematic review or clinical trial has identified an effective systemic regimen for an unresectable SFT to date. However, it has been proven that standard chemotherapy regimens may only have limited efficacy in SFT. The combination of temozolomide and bevacizumab had a remarkably high rate of overall response and a favorable duration of disease control; temozolomide/bevacizumab is a promising therapeutic regimen that warrants further investigation.
When complete resection is impossible or when there is recurrence, radiotherapy can be used, but a negative surgical margin does not mean that radiotherapy is unnecessary. Postoperative radiotherapy may theoretically reduce the risk of local recurrence; therefore, postoperative radiotherapy should be used as an adjunctive therapy in all patients . In our case, we also used TACE for arterial embolization several days before operation. TACE is an option to generate tumor hypotrophy for a better resection and reduced hemorrhagic risk. Almost all reports agree that a complete surgical resection with tumor-free margins remains the cornerstone of treatment because of the reported 10-year overall survival rates of 54-89% . The current case had widespread skeletal metastases; therefore, we used chemotherapy (adriamycin and ifosfamide), but this systemic regimen seemed to be inadequate. We believe that this report will contribute to understanding the natural history of liver SFTs.
SFTs of the liver are a rare neoplasm that cannot be definitely diagnosed by characteristic histological and immunohistochemical properties. A complete surgical resection with tumor-free margins is the best choice for treatment. Postoperative adjuvant chemotherapy or radiotherapy should be used in malignant SFTs; however, the use of these therapies in benign SFTs is still controversial.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Klemperer P, Rabin CB: Primary neoplasm of the pleura: a report of five cases. Arch Pathol Lab Med. 1931, 11: 385-412.Google Scholar
- Guillou L, Fletcher JA, Fletcher CDM, Mandahl N: Extrapleural solitary fibrous tumor and hemangiopericytoma. Pathology and Genetics of Tumours of Soft Tissues and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon, France: IARC Press, 86-Google Scholar
- Churg A, Cagle PT, Roggli VL: Solitary fibrous tumor. Tumors of the Serosal Membranes. 2006, Washington, DC: American Registry of Pathology Press, 299-4Google Scholar
- Chan JK: Solitary fibrous tumour--everywhere, and a diagnosis in vogue. Histopathology. 1997, 31: 568-576. 10.1046/j.1365-2559.1997.2400897.x.View ArticlePubMedGoogle Scholar
- Ji Y, Fan J, Xu Y, Zhou J, Zeng HY, Tan YS: Solitary fibrous tumor of the liver. Hepatobiliary Pancreat Dis Int. 2006, 5: 151-153.PubMedGoogle Scholar
- Filosso PL, Asioli S, Ruffini E: Radical resection of a giant, invasive and symptomatic malignant Solitary Fibrous Tumour (SFT) of the pleura. Lung Cancer. 2009, 64: 117-120. 10.1016/j.lungcan.2008.10.006.View ArticlePubMedGoogle Scholar
- Bishop JA, Rekhtman N: Malignant Solitary Fibrous Tumor Cytopathologic Findings and Differential Diagnosis. Cancer (Cancer Cytopathol). 2010, 118 (2): 83-9. 10.1002/cncy.20069.View ArticleGoogle Scholar
- Dalton WT, Zolliker AS, McCaughey WT, Jacques J, Kannerstein M: Localized primary tumors of the pleura: an analysis of 40 cases. Cancer. 1979, 44: 1465-75. 10.1002/1097-0142(197910)44:4<1465::AID-CNCR2820440441>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
- England DM, Hochholzer L, McCarthy MJ: Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989, 13: 640-58. 10.1097/00000478-198908000-00003.View ArticlePubMedGoogle Scholar
- Witkin GB, Rosai J: Solitary fibrous tumor of the mediastinum. A report of 14 cases. Am J Surg Pathol. 1989, 13: 547-57. 10.1097/00000478-198907000-00002.View ArticlePubMedGoogle Scholar
- Park M, Patel S, Ludwig J, Trent J, Conrad C, Lazar A, Wang W, Boonsirikamchai P, Choi H, Wang X, Benjamin R, Araujo D: Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor. Cancer. 2011,Google Scholar
- Yilmaz S, Kirimlioglu V, Ertas E, Hilmioglu F, Yildirim B, Katz D, Mizrak B: Giant Solitary Fibrous Tumor of the Liver with Metastasis to the Skeletal System Successfully Treated with Trisegmentectomy. Digestive Diseases and Sciences. 2000, 45: 168-174. 10.1023/A:1005438116772.View ArticlePubMedGoogle Scholar
- Chan G, Horton P, Thyssen S, Lamarche M, Nahal A, Hill D, Marliss E, Metrakos P: Malignant transformation of a solitary fibrous tumor of the liver and intractable hypoglycemia. J Hepatobiliary Pancreat Surg. 2007, 14: 595-9. 10.1007/s00534-007-1210-0.View ArticlePubMedGoogle Scholar
- Brochard C, Michalak S, Aubé C, Singeorzan C, Fournier HD, Laccourreye L, Calès P, Boursier J: A not so solitary fibrous tumor of the liver. Gastroentérologie Clinique et Biologique. 2010, 34: 716-720. 10.1016/j.gcb.2010.08.004.View ArticlePubMedGoogle Scholar
- Moran C, Ishak K, Goodman Z: Solitary fibrous tumor of the liver: a clinicopathologic and immunohistochemical study of nine cases. Ann Diagn Pathol. 1998, 2: 19-24.View ArticlePubMedGoogle Scholar
- Nakamura S, Fukui M, Takeshita H, Tsuji Y, Murata H, Kubo T: Malignant solitary fibrous tumor of the thigh accompanied by hypoglycemic coma. A case report. Anticancer Res. 2005, 25: 2461-4.PubMedGoogle Scholar
- Jia C, Shi S, Zhao Z, Zhen S: Solitary fibrous tumor of the liver: retrospective study of reported cases. Cancer Invest. 2006, 24: 132-5. 10.1080/07357900500524348.View ArticleGoogle Scholar
- Neeff H, Obermaier R, Technau-Ihling K, Werner M, Kurtz C, Imdahl A, Hopt UT: Solitary fibrous tumour of the liver: case report and review of the literature. Langenbecks Arch Surg. 2004, 389: 293-298.View ArticlePubMedGoogle Scholar
- Fuksbrumer M, Klimstra D, Panicek D: Solitary fibrous tumor of the liver: imaging findings. AJR Am J Roentgenol. 2000, 175: 1683-1687.View ArticlePubMedGoogle Scholar
- Guglielmi A, Frameglia M, Iuzzolino P, Martignoni G, DeManzoni G, Laterzi E, Veraldi G, Girlanda R: Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycemia. J Hepatobiliary Pancreat Surg. 1998, 5: 212-6. 10.1007/s005340050036.View ArticlePubMedGoogle Scholar
- Kandpal H, Sharma R, Gupta SD, Kumar A: Solitary fibrous tumour of the liver: a rare imaging diagnosis using MRI and diffusion-weighted imaging. The British Journal of Radiology. 2008, 81: e282-e286. 10.1259/bjr/98393711.View ArticlePubMedGoogle Scholar
- Chen J, Ong S, Richards C, Garcea G, Pollard C, Berry D, Dennison A: Inaccuracy of Fine-needle Biopsy in the Diagnosis of Solitary Fibrous Tumour of the Liver. Asian J Surg. 2008, 31 (4): 195-8. 10.1016/S1015-9584(08)60085-8.View ArticlePubMedGoogle Scholar
- Clayton A, Salomao D, Keeney G, Nascimento A: Solitary fibrous tumor: a study of cytologic features of six cases diagnosed by fine-needle aspiration. Diagn Cytopathol. 2001, 25: 172-6. 10.1002/dc.2032.View ArticlePubMedGoogle Scholar
- Novais P, Robles-Medranda C, Pannain VL, Barbosa D, Biccas B, Fogaça H: Solitary Fibrous Liver Tumor: Is Surgical Approach the Best Option?. March. 2010, 19 (1): 81-84.Google Scholar
- Korkolis D, Apostolaki K, Aggeli C, Plataniotis G, Gontikakis E, Volanaki D, Sebastiadou M, Dimitroulopoulos D, Xinopoulos D, Zografos G, Vassilopoulos P: Solitary fibrous tumor of the liver expressing CD34 and vimentin: A case report. World J Gastroenterol. 2008, 14 (40): 6261-6264. 10.3748/wjg.14.6261.PubMed CentralView ArticlePubMedGoogle Scholar
- Archontaki M, Korkolis D, Arnogiannaki N, Hatzijiannis S, Dendrinos P, Megapanos C, Kassotakis D, Kokkalis G: Histologically Malignant Solitary Fibrous Tumour of the Anterior Thoracic Wall: A Case Report and Review of the Literature. Case Reports in Medicine. 2010, 257167-257171.Google Scholar
- Yang X, Zheng J, Ye W, Wang Y, Zhu H, Wang L, Zhang Z: Malignant solitary fibrous tumors of the head and neck: A clinicopathological study of nine consecutive patients. Oral Oncology. 2009, 45: 678-682. 10.1016/j.oraloncology.2008.10.013.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.